Search Results for "Edurant"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Edurant. Results 1 to 5 of 5 total matches.
See also: rilpivirine
Rilpivirine (Edurant) - A New Drug for HIV Infection
The Medical Letter on Drugs and Therapeutics • Aug 22, 2011 (Issue 1371)
Rilpivirine (Edurant) - A New Drug for HIV Infection ...
The FDA has approved rilpivirine (Edurant –
Janssen), a non-nucleoside reverse transcriptase
inhibitor (NNRTI), for use with other antiretroviral
agents for treatment of HIV-1 infection in treatment-naive
adults. Rilpivirine is also available in a fixed-dose
combination with emtricitabine and tenofovir
(Complera – Gilead).
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
rilpivirine (Edurant) as a daily one-month lead-in
regimen before starting treatment with the monthly
IM ...
The FDA has approved Cabenuva (ViiV Healthcare),
an extended-release formulation of the new integrase
strand transfer inhibitor (INSTI) cabotegravir
copackaged with an extended-release formulation
of the non-nucleoside reverse transcriptase inhibitor
(NNRTI) rilpivirine, as a once-monthly complete
regimen for intramuscular (IM) treatment of adults
with HIV-1 infection who are virologically suppressed
(HIV-1 RNA...
Juluca - A Two-Drug Complete Regimen for HIV (online only)
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
inhibitor (NNRTI) rilpivirine (Edurant), as a oncedaily
complete regimen for treatment of adults
with HIV ...
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase
strand transfer inhibitor (INSTI) dolutegravir (Tivicay)
and the non-nucleoside reverse transcriptase
inhibitor (NNRTI) rilpivirine (Edurant), as a once-daily
complete regimen for treatment of adults
with HIV-1 infection who do not have a history of
treatment failure or known substitutions associated
with resistance to either drug and have been taking
a stable suppressive antiretroviral regimen for ≥6
months. Dolutegravir/rilpivirine is the first complete
regimen to be approved for...
Drugs for HIV Infection
Treatment Guidelines from The Medical Letter • Feb 01, 2014 (Issue 138)
– Viramune XR 100, 400 mg tabs 400 mg once/d14 1 592.40
Rilpivirine [RPV] – Edurant (Janssen)15 25 mg tabs ...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019 (Issue 1579)
of dolutegravir and the non-nucleoside
reverse transcriptase inhibitor (NNRTI) rilpivirine
(Edurant ...
The FDA has approved Dovato (ViiV), a fixed-dose
combination of the integrase strand transfer inhibitor
(INSTI) dolutegravir (Tivicay) and the nucleoside
reverse transcriptase inhibitor (NRTI) lamivudine
(Epivir, and generics), as a once-daily complete
regimen for treatment of adults with HIV-1 infection
who are antiretroviral-treatment naive and have no
known substitutions associated with resistance
to either drug. Dolutegravir/lamivudine is the first
complete regimen to be approved by the FDA for
initial treatment of HIV-1 infection that contains 2
rather than 3 antiretroviral...